Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 802,800 shares, a decrease of 8.7% from the November 15th total of 879,600 shares. Based on an average daily volume of 285,600 shares, the short-interest ratio is presently 2.8 days. Approximately 1.4% of the company's shares are sold short.
Context Therapeutics Stock Performance
NASDAQ CNTX traded down $0.03 during trading on Monday, reaching $1.36. 361,481 shares of the company's stock were exchanged, compared to its average volume of 300,225. The company has a 50 day moving average price of $1.84 and a two-hundred day moving average price of $2.04. Context Therapeutics has a 1 year low of $0.89 and a 1 year high of $2.75. The stock has a market cap of $102.00 million, a P/E ratio of -1.47 and a beta of 2.00.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.11). Research analysts forecast that Context Therapeutics will post -0.51 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on CNTX. HC Wainwright reissued a "buy" rating and set a $6.00 price target on shares of Context Therapeutics in a research report on Monday, September 23rd. D. Boral Capital assumed coverage on shares of Context Therapeutics in a report on Monday, November 25th. They issued a "buy" rating and a $9.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $6.80.
Read Our Latest Stock Report on Context Therapeutics
Hedge Funds Weigh In On Context Therapeutics
Institutional investors have recently added to or reduced their stakes in the stock. Great Point Partners LLC purchased a new position in shares of Context Therapeutics in the 2nd quarter valued at about $14,876,000. Blue Owl Capital Holdings LP purchased a new position in shares of Context Therapeutics in the second quarter valued at $10,348,000. Driehaus Capital Management LLC acquired a new position in shares of Context Therapeutics during the 2nd quarter worth $4,527,000. Nantahala Capital Management LLC purchased a new stake in shares of Context Therapeutics in the 2nd quarter worth about $3,881,000. Finally, Franklin Resources Inc. acquired a new stake in Context Therapeutics in the 3rd quarter valued at about $3,689,000. Institutional investors and hedge funds own 14.03% of the company's stock.
About Context Therapeutics
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Read More
Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
